# Instinct Bio Technical Company Holdings Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Instinct Bio Technical Company Holdings Inc). ## Overview Instinct Bio Technical Co Holdings Inc. is a U.S.-listed holding company with operations centered on Japanese aesthetic-healthcare and regenerative-medicine businesses in Asia and related international markets. Its reported business includes the GENRÊVER CLINIC brand, cosmetic products, and a broader platform built around stem-cell, iPS-cell, exosome, and conditioned-media technologies. ## Products & services • GENRÊVER CLINIC subscription-model beauty clinics • Japanese-brand aesthetic healthcare services • GENRÊVER cosmetic products • Regenerative-medicine platform and related biological inputs • Exosomes and conditioned media supply for clinics • In-hospital cell processing and laboratory services - **Aesthetic clinics** (35%) — Directly operated beauty and medical-aesthetics clinics under the GENRÊVER brand. - **Cosmetic products** (20%) — Brand-led skincare and beauty products sold in the United States and other markets. - **Regenerative medicine inputs** (20%) — Biological materials such as exosomes and conditioned media used in clinic workflows. - **Cell therapy services** (15%) — Cell processing, laboratory support, and related regenerative-medicine services. - **Membership subscriptions** (10%) — Recurring clinic membership fees from the subscription-model aesthetic offering. - GENRÊVER CLINIC subscription-model beauty clinics - Japanese-brand aesthetic healthcare services - GENRÊVER cosmetic products - Regenerative-medicine platform and related biological inputs - Exosomes and conditioned media supply for clinics - In-hospital cell processing and laboratory services ## Customers The company serves consumers seeking aesthetic and wellness treatments through subscription-based clinics, as well as customers buying branded cosmetic products. It also addresses clinics, laboratories, and healthcare partners that may use exosomes, conditioned media, or other regenerative-medicine inputs in treatment workflows. - **Clinic members** (primary) — Individual consumers who pay flat-fee membership charges for ongoing aesthetic services and treatments. - **Cosmetics buyers** (secondary) — Retail or direct customers purchasing GENRÊVER-branded cosmetic products for personal use. - **Medical aesthetics partners** (secondary) — Clinics and practitioners that may source regenerative inputs and related support services. - **Regenerative medicine collaborators** (emerging) — Healthcare or laboratory partners involved in cell-processing, exosome, or conditioned-media workflows. - Consumers buying recurring aesthetic clinic memberships - Beauty and wellness patients seeking non-surgical treatments - U.S. customers purchasing GENRÊVER cosmetic products - Clinics needing exosomes and conditioned media supplies - Healthcare partners using cell-processing and lab services ## Geography The company is headquartered in the United States but its reported operating focus spans Japan and Indonesia, with additional plans for U.S. cosmetic-product activity. Its clinic rollout and regenerative-medicine initiatives are tied to Indonesia’s major metropolitan areas, while product and brand development are connected to Japanese sourcing and manufacturing capabilities. - United States is the corporate base and a target market for cosmetics - Japan anchors the GENRÊVER brand and product-development identity - Indonesia is the main clinic expansion market in the disclosed strategy - Five major Indonesian metropolitan areas are targeted for initial clinics - Cross-border operations link U.S., Japanese, and Indonesian execution ## Strategy The company’s stated direction is to build recurring revenue through a subscription-based clinic model while extending the GENRÊVER brand into additional markets. It is also pursuing regenerative-medicine applications that could connect consumer clinics, product sales, and biological supply relationships into one platform. - **Open the first wave of Indonesian clinics** (short-term) — Creates the initial recurring-revenue base and tests the subscription model in a large aesthetics market. - **Expand GENRÊVER cosmetics in the United States** (medium-term) — Extends the brand beyond clinics and diversifies revenue into product sales. - **Develop regenerative-medicine capabilities** (medium-term) — Links the clinic model to higher-value biological products and services. - Launch subscription-model beauty clinics in Indonesia - Use GENRÊVER as the core brand across clinic and product channels - Expand cosmetic-product manufacturing and sales in the United States - Develop regenerative-medicine partnerships and supply capabilities - Build a recurring-revenue platform around memberships and services ## Risks The business depends on successfully launching a new clinic model in Indonesia and scaling it without disrupting service quality or unit economics. It also faces execution, regulatory, and commercialization risk around regenerative-medicine products and cross-border manufacturing, where clinical, legal, and supply-chain requirements can change materially. - **Clinic rollout and membership adoption risk** [high] — The company is introducing a subscription beauty-clinic model that has to attract and retain enough members to support expansion. - **Regulatory and licensing risk** [high] — Aesthetic clinics, biological inputs, and cell-related services may require approvals that differ by country and service type. - **Regenerative-medicine commercialization risk** [high] — Exosomes, conditioned media, and cell-processing services are highly sensitive to clinical acceptance, safety, and legal constraints. - **Cross-border supply-chain risk** [medium] — The business relies on Japanese brand development, U.S. manufacturing capability, and Indonesian market execution. - New clinic format may not gain enough membership adoption - Indonesia healthcare and aesthetics regulation may restrict rollout - Regenerative-medicine commercialization faces clinical and legal risk - Cross-border manufacturing and supply chains add execution complexity - Consumer aesthetics demand can be cyclical and preference-driven ## Accounting The company will likely face judgment in recognizing subscription revenue from clinic memberships, cosmetic-product sales, and any service arrangements that may span multiple periods. Capitalized development or acquisition-related costs, fair-value measurements tied to financing, and impairment of intangible assets may also matter because the business is still building a multi-country platform. - **Subscription revenue recognition** — Affects timing of revenue and deferred revenue balances - **Product revenue recognition** — Affects gross revenue and reserve estimates - **Intangible asset impairment** — Could cause non-cash write-downs - **Development and launch costs** — Affects operating expenses and asset capitalization - Membership revenue timing depends on service delivery and cancellation terms - Product sales recognition depends on transfer of control and returns - Development and launch costs may be expensed or capitalized - Acquisition-related intangibles may require impairment testing - Equity financing and fair-value assumptions may affect reported results --- *Last updated: 2026-09-28T12:04:02.973520+00:00*